Navigation Links
Xlumena Closes Series C Financing; Focuses on Expanding Global Commercial Presence and Obtaining FDA Clearance
Date:12/3/2013

MOUNTAIN VIEW, Calif., Dec. 3, 2013 /PRNewswire/ -- Xlumena, Inc., a leader in the development of advanced endoscopic devices, today announced the close of a $25 million Series C financing.  Led by Third Point LLC, the round of funding includes existing investors Prism VentureWorks, Charter Life Sciences, Ascent Biomedical Ventures and Aperture Venture Partners.  Xlumena will use the Series C proceeds to expand global commercialization efforts for its AXIOS family of devices and continue the process of bringing this innovative platform to the US interventional endoscopy community. 

Xlumena's principal product, the AXIOS Stent and Delivery System, obtained a CE mark designation in Europe in 2012 and is available in a select number of centers.  The AXIOS Stent, a fully-covered, dual-flanged stent, is delivered under endoscopic ultrasound guidance and designed to create a secure drainage pathway between the gastrointestinal tract and the common bile duct, gallbladder or pseudocyst.  The HOT AXIOS, also available in Europe, incorporates cautery into the delivery system, enabling access and stent delivery in a single device.  The AXIOS devices have been used in the treatment of acute cholecystitis, biliary inflammation associated with strictures or stones in the bile duct, and pancreatic pseudocysts.

Greg Patterson, President and CEO of Xlumena, commented: "As a company, we have always focused on the needs of interventional endoscopists. This financing will allow us to better meet the global commercial demand and provide a springboard for an initial launch of the AXIOS in the United States once FDA clearance is granted. We look forward to this new collaboration with Third Point and a continued partnership with our existing investors."  Jason Hong Ph.D. will represent Third Point LLC on the Xlumena Board of Directors. 

For more information about the AXIOS Stent and Delivery System, please visit www.xlumena.com.

About Xlumena, Inc.: Xlumena is the leader in developing products that enable advanced image-guided endoscopy procedures. These innovations will allow endoscopists to offer minimally invasive alternatives to patients suffering from common gastrointestinal and biliary conditions. Pioneering interventional endoscopists around the world are using Xlumena's products to extend their therapeutic reach. 

About Third Point: Third Point LLC is an SEC-registered investment adviser headquartered in New York. Founded in 1995, Third Point follows an event-driven approach to global investing.

CAUTION: The AXIOS and HOT AXIOS devices have CE mark designation in Europe. They are not available for sale in the United States. 


'/>"/>
SOURCE Xlumena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Tyber Medical Closes Private Placement Funding Round
2. Catabasis Closes $32.4 Million Series B Financing
3. CorMedix Inc. Closes $3,000,000 Preferred Stock Offerings
4. TREVENTIS Corporation Closes $4.4 Million Financing with Wellcome Trust
5. Apama Medical, A Shifamed Portfolio Company, Closes $3.2M Series A-1 Financing Round
6. MEDTEC China 2013: Conference Program Closes in on Finalization
7. Drip Drop Inc. closes $3.0M Series A-1 round with investments from John Elway, Ronnie Lott, and Sam Nazarian.
8. Acutus Medical Closes Series B Funding at $28 Million
9. Organovo Holdings, Inc. Closes $46.6 Million Public Offering of Common Stock and Exercise of Over-Allotment Option
10. Endexx closes Acquisition of Dispense Labs LLC.
11. AuraSense Therapeutics Closes Tranche II of Series B Equity Investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):